Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms
The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Abstract
Aim This study examined the efficacy of sertindole in comparison with a selective 5-HT(6) and a 5-HT(2A) receptor antagonist to reverse sub-chronic phencyclidine (PCP)-induced cognitive deficits in female rats.Methods In the first test, adult female hooded Lister rats were trained to perform an operant reversal learning task to 90% criterion. After training, rats were treated with PCP at 2 mg/kg (i.p.) or vehicle twice daily for 7 days, followed by 7 days washout. For the second test, novel object recognition (NOR), a separate batch of rats, had the same sub-chronic PCP dosing regime and washout period. In reversal learning, rats were treated acutely with sertindole, the selective 5-HT(2A) receptor antagonist M100.907 or the selective 5-HT(6) receptor antagonist SB-742457.Results The PCP-induced selective reversal learning deficit was significantly improved by sertindole, M100.907 and SB-742457. Sertindole also significantly improved the sub-chronic PCP-induced deficit in NOR, a test of episodic memory following a 1 min and 1 h inter-trial interval. In vivo binding studies showed that the dose-response relationship for sertindole in this study most closely correlates with affinity for 5-HT(6) receptor in vivo binding in striatum, although contribution from binding to 5-HT(2A) receptors in vivo in cortex may also provide an important mechanism.Conclusion The efficacies of selective 5-HT(2A) and 5-HT(6) receptor antagonists suggest potential mechanisms mediating the effects of sertindole, which has high affinity for these 5-HT receptor subtypes. The sertindole-induced improvement in cognitive function in this animal model suggests relevance for the management of cognitive deficit symptoms in schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In PCP-treated rats, the 5-HT6 receptor antagonist, SB 271046, and sertindole, a second generation antipsychotic that acts as an antagonist on several neurotransmitter receptors, with high affinity for the 5-HT6 receptor, reduced the PCP-induced deficit in set-shifting (Idris et al 2010, Rodefer et al 2008).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Idris et al 2010
Citations
Cites
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Impaired Recognition Memory in Rats after Damage to the Hippocampus
Clark, R. E., Zola, S. M., & Squire, L. R. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-23-08853.2000 · Cited by 738
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Self-citationKeefe, R. S. E., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033374 · Cited by 693
The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents
Dere, E., Huston, J. P., & De Souza Silva, M. A. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.01.005 · Cited by 675
Object recognition memory: Neurobiological mechanisms of encoding, consolidation and retrieval
Winters, B. D., Saksida, L. M., & Bussey, T. J. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.04.004 · Cited by 572
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544 · cited 1×
“Indeed D1 receptor agonists have been suggested as a target for improvement of cognition in schizophrenia ( Goldman-Rakic et al. 2004 ).”
BackgroundBilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
Kapur, S., VanderSpek, S. C., Brownlee, B. A., & Nobrega, J. N. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046987 · Cited by 479
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Cognitive Deficits in Schizophrenia
Gold, J. M., & Harvey, P. D. (1993) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30175-8 · Cited by 365
Jentsch, J. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00034-1 · Cited by 320
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.782 · Cited by 306
Dopamine, the prefrontal cortex and schizophrenia
Knable, M. B., & Weinberger, D. R. (1997) · Journal of Psychopharmacology · doi:10.1177/026988119701100205 · Cited by 303
Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia
Abi-Dargham, A., & Moore, H. (2003) · The Neuroscientist · doi:10.1177/1073858403252674 · Cited by 277
5-HT6 Receptor Antagonists as Novel Cognitive Enhancing Agents for Alzheimer's Disease
Upton, N., Chuang, T. T., Hunter, A. J., & Virley, D. J. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.008 · Cited by 255
Dawson, L. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00265-2 · Cited by 245
GRAYSON, B., IDRIS, N., & NEILL, J. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.06.012 · Cited by 243
Self-citationInfluence of gender on working and spatial memory in the novel object recognition task in the rat
Sutcliffe, J. S., Marshall, K. M., & Neill, J. C. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.10.029 · Cited by 240
Self-citationHirst, W. D., Stean, T. O., Rogers, D. C., Sunter, D., Pugh, P., Moss, S. F., Bromidge, S. M., Riley, G., Smith, D. R., Bartlett, S., et al. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.09.049 · Cited by 234
Abdul-Monim, Z., Neill, J. C., & Reynolds, G. P. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107067097 · Cited by 206 · cited 4×
“We have recently shown enduring cognitive deficits in rodents following a 7-day treatment regime with the NMDA receptor antagonist, phencyclidine (PCP), in several tests of relevance to schizophrenia and listed in TURNS, in addition to social behaviour deficits ( Abdul-Monim et al. 2006, 2007; Grayson et al. 2007; McL…”
BackgroundMethodInfluentialSelf-citationZhang, W., & Bymaster, F. P. (1999) · Psychopharmacology · doi:10.1007/s002130050834 · Cited by 159
Abdul-Monim, Z., Reynolds, G. P., & Neill, J. C. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.01.019 · Cited by 157
Self-citationInsight and neurocognition in schizophrenia.
Drake, R., & Lewis, S. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00382-1 · Cited by 152
Neurocognitive Deficits in Schizophrenia
Goldberg, T. E., David, A. S., & Gold, J. M. (2003) · Wiley eBooks · doi:10.1002/9780470987353.ch10 · Cited by 142
Idris, N. F., Repeto, P., Neill, J. C., & Large, C. H. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2058-5 · Cited by 131
Self-citationSchmidt, C. J., & Fadayel, G. M. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)00698-7 · Cited by 126
Rodefer, J. S., Nguyen, T. N., Karlsson, J.-J., & Arnt, J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301654 · Cited by 126 · cited 5×
“Our studies demonstrate that sertindole, at relevant doses and plasma exposure levels approximating those seen clinically (Rodefer et al. 2008), ameliorates the reversal learning and the episodic memory deficits induced by subchronic PCP.”
BackgroundInfluentialSelf-citation5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats
Hatcher, P. D., Brown, V. J., Tait, D. S., Bate, S. T., Overend, P., Hagan, J. J., & Jones, D. N. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2261-z · Cited by 117
Jentsch, J., & Taylor, J. R. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00174-3 · Cited by 117
Goetghebeur, P., & Dias, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1132-9 · Cited by 113
Loiseau, F., Dekeyne, A., & Millan, M. J. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0934-5 · Cited by 113
Harvey, P. D., Meltzer, H. Y., Simpson, G. M., Potkin, S. G., Loebel, A. D., SIU, C. O., & Romano, S. J. (2003) · Schizophrenia Research · doi:10.1016/j.schres.2003.07.009 · Cited by 104
Abdul-Monim, Z., Reynolds, G. P., & Neill, J. C. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103017001700 · Cited by 101
Self-citationSnigdha, S., & Neill, J. C. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.03.018 · Cited by 96
Self-citationMcLean, S. L., Beck, J. P., Woolley, M. L., & Neill, J. C. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.12.029 · Cited by 89
Self-citationDidriksen, M., Skarsfeldt, T., & Arnt, J. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0774-3 · Cited by 85
Self-citationHashimoto, K., Fujita, Y., Ishima, T., Chaki, S., & Iyo, M. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.07.009 · Cited by 78
Snigdha, S., & Neill, J. C. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.10.012 · Cited by 74
Self-citationHyttel, J., Nielsen, J. B., & Nowak, G. (1992) · Journal of Neural Transmission · doi:10.1007/bf01245352 · Cited by 73
Frånberg, O., Wiker, C., Marcus, M. M., Konradsson‐Geuken, Å., Jardemark, K. E., Schilström, B., Shahid, M., Wong, E. H. F., & Svensson, T. H. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0973-y · Cited by 68
McLean, S. L., Idris, N. F., Woolley, M. L., & Neill, J. C. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.01.009 · Cited by 67
Self-citation[3H]GBR 12935 binding in vivo in mouse brain: labelling of a piperazine acceptor site
Andersen, P. H., Jansen, J. A., & Nielsen, E. B. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90002-1 · Cited by 57
Depoortère, R., Auclair, A. L., Bardin, L., Slot, L. B., Kleven, M. S., Colpaert, F., Vacher, B., & Newman‐Tancredi, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707160 · Cited by 55
Executive function in schizophrenia: what impact do antipsychotics have?
O'Grada, C., & Dinan, T. (2007) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.861 · Cited by 48
Azorin, J.-M., Strub, N., & Loft, H. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000177020.26311.a7 · Cited by 48
Gallhofer, B., Jaanson, P., Mittoux, A., Tanghøj, P., Lis, S., & Krieger, S. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-990291 · Cited by 48
Nyberg, S., Olsson, H., Nilsson, U., Mæhlum, E., Halldin, C., & Farde, L. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1083-5 · Cited by 44
Mørk, A., Witten, L. M., & Arnt, J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1578-4 · Cited by 40
Self-citationEffects of repeated treatment of phencyclidine on cognition and gene expression in C57BL/6 mice
Beraki, S., Heijtz, R. D., Tai, F., & Ögren, S. O. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009152 · Cited by 40
Receptor profile of antipsychotics
Leysen, J. E. (2000) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8448-8_4 · Cited by 35
Dunn, M. J., & Killcross, S. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.08.028 · Cited by 31 · cited 1×
“working memory in the water maze in rats and mice (Beraki et al. 2009) and in novel object recognition (NOR) in mice (Hashimoto et al. 2008) and in a test of conditional discrimination in rats ( Dunn and Kilcross 2006 ).”
BackgroundNon-equipotent doses partly explain differences among antipsychotics - implications of PET studies
Nyberg, S., & Farde, L. (2000) · Psychopharmacology · doi:10.1007/s002130050020 · Cited by 28
The psychopharmacology of schizophrenia
Fleischhacker, W. W. (1999) · Current Opinion in Psychiatry · doi:10.1097/00001504-199901000-00017 · Cited by 27
Neurocognitive and social functioning in schizophrenia and other diagnoses
Addington, J., Addington, D. E., & Gasbarre, L. M. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00103-1 · Cited by 25
Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic
Kane, J. M., & Tamminga, C. A. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.11.1729 · Cited by 21
Olanzapine (Zyprexa):charactirestics of a new antipsychotic
Tamminga, C. A., & Kane, J. M. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.11.1743 · Cited by 17
Strategies for pharmacotherapy of schizophrenia
Arnt, J., Bang‐Andersen, B., Dias, R. D. S., & Bøgesø, K. P. (2008) · Drugs of the Future · doi:10.1358/dof.2008.033.09.1236966 · Cited by 17
Self-citationStuchlík, A., Petrásek, T., & Valeš, K. (2009) · Physiological Research · doi:10.33549/physiolres.931636 · Cited by 17
Neurocognitive Deficits in Schizophrenia
Yager, J. (1996) · Journal watch · doi:10.1056/jp199606010000010 · Cited by 17
Snigdha, S., Neill, J. C., Shahid, M., Cruise, L., & Henry, B. (2007) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(07)70353-x · Cited by 8
Self-citation
Research works printed but not linked: 2
- Grayson B, Kurin A, Neill JC (2008) J Psychopharmacol Abstract supplement to volume 22(5):A16
- Neill JC, Shahid M, Wong EHF, Idris NF (2006) Comparison of the efficacy of asenapine, risperidone and olanzapine to improve a reversal learning deficit in the rat. Schiz Res 81:105–106
Cited by
Animal models of schizophrenia
Jones, C., Watson, D., & Fone, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01386.x · Cited by 771
“, 2010) and reasoning and problem solving (attentional set-shifting, operant reversal learning and maze tasks) (Rodefer et al., 2005; Abdul-Monim et al., 2006; Didriksen et al., 2007; Beraki et al., 2008; Egerton et al., 2008; Pedersen et al., 2009; Idris et al., 2010), but to date we are unaware of any studies evalua…”
BackgroundNeill, J. C., Barnes, S., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., & Harte, M. K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.004 · Cited by 530
“We have also demonstrated efficacy of sertindole (Idris et al., 2010), and several novel agents including the 5-HT6 receptor antagonist, Lu AE58054 (Arnt et al. 2010); ampakines, CX546 and CX516 (Daamgard et al. 2010) and the full agonist at α7 nicotinic receptors, PNU282987 (McLean et al. 2010a).”
BackgroundResultInfluentialSelf-citationMaeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., Ito, N., McQuade, R. D., Mørk, A., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213793 · Cited by 372
“In Vivo Binding to rD2, r5-HT2A, and r5-HT6 Receptors in Rat Brain Occupancy for the D2, 5-HT2A, and 5-HT6 receptors was measured by in vivo binding with [3H]raclopride (D2 receptor binding), [3H]M100907 (5-HT2A binding), or [ 3H]Lu AE60157 (5-HT6 binding), respectively (Idris et al., 2010).”
MethodSelf-citationGilmour, G., Dix, S., Fellini, L., Gastambide, F., Plath, N., Steckler, T., Talpos, J., & Tricklebank, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.03.015 · Cited by 184
“, 1997), while novel object recognition (Damgaard et al., 2010; Grayson et al., 2007; Harte et al., 2007; Hashimoto et al., 2005; Idris et al., 2010; McLean et al., 2009a,b; Nagai et al., 2009; Pichat et al., 2007), and water maze acquisition is impaired (Didriksen et al.”
InfluentialPrefrontal cortex executive processes affected by stress in health and disease
Girotti, M., Adler, S. M., Bulin, S. E., Fucich, E. A., Paredes, D., & Morilak, D. A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.004 · Cited by 176
Metadata
- Authors
- Idris, N., Neill, J., Grayson, B., Bang-Andersen, B., Witten, L. M., Brennum, L. T., & Arnt, J.
- Affiliations
- University of Bradford (GB)
- Lundbeck (Denmark) (DK)
- Venue
- Psychopharmacology
- Published
- 2009-10-23
- Volume
- 208
- Issue
- 1
- Pages
- 23-36
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2080964010
- Cited by
- 74
- References
- 66
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 4 · 2018: 6 · 2017: 7 · 2015: 8 · 2014: 5 · 2013: 3 · 2012: 5
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- sertindole, reversal learning, episodic memory, novel object recognition, 5-HT2A receptor antagonism, schizophrenia, cognitive impairment, striatum, cortex, female rats
- MeSH terms
- Animals, Cognition Disorders, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Fluorobenzenes, Imidazoles, Indoles, Memory Disorders, Phencyclidine, Piperidines, Quinolines, Receptors, Serotonin, Reversal Learning, Schizophrenia, Sulfones, Antipsychotic Agents, Receptor, Serotonin, 5-HT2A, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.